Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,440 stopped studies mapped to Adenocarcinoma and descendants · 92% state a reason
Over the 1,440 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04370509 | Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients… | Phase 2 | terminated | May 1, 2020 | University of California, San Francisco | Collaborating sponsor decision | Sponsor / business decision |
| NCT05417386 | FOLFIRINOX + NIS793 in Pancreatic Cancer | Phase 1 | terminated | Jun 14, 2022 | Colin D. Weekes, M.D., PhD | NIS793 is no longer being developed | Other (stated, no rule matched) |
| NCT06994299 | A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab…(PRISM) | Phase 2 | withdrawn | May 29, 2025 | Weill Medical College of Cornell University | Drug and financial support not available for the study. | Funding |
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety… | Phase 2 | terminated | Feb 25, 2022 | SOTIO Biotech AG | Due to lack of expected efficacy shown at the time of the interim analysis | Efficacy / futility |
| NCT06052852 | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With… | Phase 1 | terminated | Sep 25, 2023 | Bolt Biotherapeutics, Inc. | Sponsor decision | Sponsor / business decision |
| NCT02936102 | A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced… | Phase 1 | terminated | Oct 18, 2016 | Novartis Pharmaceuticals | The early termination was based on a business decision that FAZ053 would no longer be formulated… | Safety / toxicity |
| NCT07178665 | Pilot Trial of Preop Partial Radiation in Breast Cancer Patients | Phase 1 | suspended | Sep 17, 2025 | Rutgers, The State University of New Jersey | 10th patient enrolled; interim analysis to be completed by HROC after 3-month follow-up completed… | Efficacy / futility |
| NCT03979508 | Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant,… | Phase 2 | terminated | Jun 7, 2019 | Mayo Clinic | The primary biomarker (CD8/FOXP3) was rarely observed to be \< 1.6 in residual tumors examined in… | Other (stated, no rule matched) |
| NCT05119335 | A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell… | Phase 1 / Phase 2 | terminated | Nov 15, 2021 | NiKang Therapeutics, Inc. | This study was terminated as a result of Sponsor portfolio reprioritization. | Sponsor / business decision |
| NCT05935748 | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell… | Phase 2 | terminated | Jul 7, 2023 | NiKang Therapeutics, Inc. | This study was terminated as a result of Sponsor portfolio reprioritization. | Sponsor / business decision |
| NCT04504916 | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors… | Phase 2 | terminated | Aug 7, 2020 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Business reasons | Sponsor / business decision |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects… | Phase 1 / Phase 2 | terminated | Jan 18, 2022 | Alaunos Therapeutics | Funding | Funding |
| NCT05252390 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients… | Phase 1 | terminated | Feb 23, 2022 | Nuvation Bio Inc. | The Sponsor has achieved its objectives. | Other (stated, no rule matched) |
| NCT04958785 | Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally…(ELEVATE TNBC) | Phase 2 | terminated | Jul 12, 2021 | Gilead Sciences | Sponsor decision to terminate study. | Sponsor / business decision |
| NCT02881554 | Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or… | N/A | terminated | Aug 29, 2016 | University of Washington | Terminated due to low accrual in Cohort B. (Accrual goal for Cohort A was met.) | Enrollment / accrual |
| NCT05033522 | Immunotherapy for Advanced Liver Cancer(ALIVE) | Phase 2 / Phase 3 | suspended | Sep 2, 2021 | Mirror Biologics, Inc. | Sponsor unable to fund | Funding |
| NCT05220722 | Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors | Phase 1 / Phase 2 | terminated | Feb 2, 2022 | TriSalus Life Sciences, Inc. | The decision was made to terminate the study after the completion of Phase 1b enrollment and not… | Safety / toxicity |
| NCT05229601 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Feb 8, 2022 | HiFiBiO Therapeutics | The decision to discontinue the trial was made as part of a strategic review of the Sponsor's… | Safety / toxicity |
| NCT03144661 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced… | Phase 1 | terminated | May 9, 2017 | Incyte Corporation | Strategic Business Decision | Sponsor / business decision |
| NCT04050462 | Nivolumab Combined With BMS-986253 in HCC Patients | Phase 2 | terminated | Aug 8, 2019 | NYU Langone Health | Study was terminated early by the drug sponsor due to slow accrual and a change in the company's… | Enrollment / accrual |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in… | Phase 1 | terminated | Feb 17, 2020 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT04419181 | Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer | Phase 2 | withdrawn | Jun 5, 2020 | University of Rochester | Change in the landscape of current treatment of early stage breast cancer. Larger clinical trials… | Other (stated, no rule matched) |
| NCT04712721 | Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3… | Early Phase 1 | terminated | Jan 15, 2021 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT04363801 | A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With…(DisTinGuish) | Phase 2 | terminated | Apr 27, 2020 | Leap Therapeutics, Inc. | experimental treatment will not be more efficacious than its comparator in the primary endpoint of… | Other (stated, no rule matched) |
| NCT03901469 | A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer(TNBC) | Phase 2 | terminated | Apr 3, 2019 | Zenith Epigenetics | Parts 1 and 2 and Expansion Cohort C were completed. Expansion Cohorts A and B were discontinued… | Safety / toxicity |
| NCT04616547 | Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy… | Phase 2 | terminated | Nov 5, 2020 | National Cancer Institute (NCI) | Insufficient drug supply | Drug supply |
| NCT05276492 | Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find… | Phase 1 | terminated | Mar 11, 2022 | University of Chicago | Closed by PI due to not meeting primary endpoint | Other (stated, no rule matched) |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | Phase 2 | terminated | Aug 2, 2021 | Day One Biopharmaceuticals, Inc. | Sponsor decision | Sponsor / business decision |
| NCT04108858 | Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance… | Phase 1 / Phase 2 | terminated | Sep 30, 2019 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT03535506 | Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for…(WI223281) | Phase 2 | terminated | May 24, 2018 | Georgetown University | lack of accrual | Enrollment / accrual |
| NCT06264921 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | terminated | Feb 20, 2024 | NiKang Therapeutics, Inc. | This study was terminated as a result of Sponsor portfolio reprioritization. | Sponsor / business decision |
| NCT06528210 | Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of… | Phase 2 | withdrawn | Jul 30, 2024 | OHSU Knight Cancer Institute | Loss of funding | Funding |
| NCT05445609 | Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic… | Phase 2 | suspended | Jul 6, 2022 | Emory University | Per sponsor memo screening and enrollment of new patients for all ongoing Regeneron sponsored… | Enrollment / accrual |
| NCT06302400 | Individualized Dosimetry for Holmium-166 Radioembolization in Patients With Unresectable…(RHEPaiR) | N/A | terminated | Mar 8, 2024 | Imperial College London | Terumo Europe NV permanently discontinued production of Holmium platform SIRT product range | Other (stated, no rule matched) |
| NCT06285097 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced… | Phase 1 | terminated | Feb 29, 2024 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT04249622 | Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based… | Phase 2 | terminated | Jan 31, 2020 | Mayo Clinic | slow accrual | Enrollment / accrual |
| NCT04278144 | A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab… | Phase 1 / Phase 2 | terminated | Feb 20, 2020 | Bolt Biotherapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT05582018 | Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of…(PANORAMA) | N/A | terminated | Oct 17, 2022 | Techsomed Medical Technologies LTD | Sponsor decision | Sponsor / business decision |
| NCT05733351 | Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With… | Phase 1 | terminated | Feb 17, 2023 | Emory University | To review the safety data. | Safety / toxicity |
| NCT05678257 | A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer | Phase 2 | terminated | Jan 10, 2023 | NuCana plc | A pre-planned initial analysis concluded that the study was unlikely to achieve its primary… | Other (stated, no rule matched) |
| NCT06690281 | A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H… | Phase 2 | withdrawn | Nov 15, 2024 | National Cancer Institute (NCI) | PI left NIH. | Investigator |
| NCT07117409 | Retrospective Study on the Safety of Nivolumab in Patients With mRCC and Renal Failure(RI-NIVO) | — | terminated | Aug 12, 2025 | Azienda USL Reggio Emilia - IRCCS | Healted Prematurely | Other (stated, no rule matched) |
| NCT07166367 | Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for… | Phase 2 | terminated | Sep 10, 2025 | National Cancer Centre, Singapore | Difficulty in enrolling patients with the illness under study. | Enrollment / accrual |
| NCT03838367 | Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine… | Phase 1 / Phase 2 | terminated | Feb 12, 2019 | CytoDyn, Inc. | Study terminated prematurely due to business reasons. Participants are no longer examined or… | Sponsor / business decision |
| NCT04502082 | Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1) | Phase 1 | terminated | Aug 6, 2020 | Eureka Therapeutics Inc. | The trial was intended to be a Phase 1/2 trial, but the sponsor terminated the trial prior to… | Other (stated, no rule matched) |
| NCT06084689 | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures(EMPIRE) | Phase 2 | withdrawn | Oct 16, 2023 | Institut Bergonié | Discontinuation of molecule development | Other (stated, no rule matched) |
| NCT03765736 | Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal… | — | terminated | Dec 5, 2018 | Academic and Community Cancer Research United | Low accrual | Enrollment / accrual |
| NCT05009979 | 18F-DCFPyL PET/CT in Hepatocellular Carcinoma | Phase 2 | terminated | Aug 18, 2021 | National Cancer Institute (NCI) | Reason for termination was a combination of slow accrual in setting of austerity measures regarding… | Enrollment / accrual |
| NCT05451862 | Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular…(HOMIE-166) | N/A | terminated | Jul 11, 2022 | Terumo Europe N.V. | The HOMIE-166 clinical investigation was prematurely terminated due to sponsor's decision to… | Sponsor / business decision |
| NCT05605522 | A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | Phase 1 | terminated | Nov 4, 2022 | 3B Pharmaceuticals GmbH | Sponsor reprioritization of active trials. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Nov 19, 2025source: clinicaltrials